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Abstract
Following an application from Zespri International Limited, submitted for authorisation of a health claim
pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Belgium,
the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion
on the scientific substantiation of a health claim related to green kiwifruit (lat. Actinidia deliciosa var.
Hayward) and maintenance of normal defecation. The scope of the application was proposed to fall
under a health claim based on newly developed scientific evidence. The food proposed by the
applicant as the subject of the health claim is green kiwifruit. The Panel considers that green kiwifruit
(Actinidia deliciosa var. Hayward) is sufficiently characterised. The claimed effect proposed by the
applicant is ‘maintenance of normal defecation’. Maintenance of normal defecation is a beneficial
physiological effect provided that it does not result in diarrhoea. All human intervention studies
submitted had different limitations and could not be used on their own for the scientific substantiation
of the claim. However, the results of six pertinent human intervention studies are consistent with
respect to an effect of consuming daily between two and four green kiwifruits var. Hayward on an
increase in stool frequency. Two out of four studies in which a validated instrument was used to assess
stool consistency showed an effect also on stool consistency. There is evidence for a plausible
mechanism by which kiwifruit could exert an effect on normal defecation. The consumption of kiwifruit
in the studies did not result in diarrhoea. A cause and effect relationship has been established between
the consumption of green kiwifruit (Actinidia deliciosa var. Hayward) and maintenance of normal
defecation. The following wordings reflect the scientific evidence: ‘consumption of kiwifruit contributes
to the maintenance of normal defecation’. In order to obtain the claimed effect, two large green
kiwifruits (i.e. around 200 g of kiwi flesh) should be consumed.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EC) No 1924/2006 harmonises the provisions that relate to nutrition and health claims,
and establishes rules governing the Community authorisation of health claims made on foods. As a
rule, health claims are prohibited unless they comply with the general and specific requirements of this
Regulation, are authorised in accordance with this Regulation, and are included in the lists of
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this
Regulation lays down provisions for the addition of claims (other than those referring to the reduction
of disease risk and to children’s development and health), which are based on newly developed
scientific evidence or include a request for the protection of proprietary data, to the Community list of
permitted claims referred to in Article 13(3). According to Article 18 of this Regulation, an application
for inclusion in the Community list of permitted claims referred to in Article 13(3) shall be submitted by
the applicant to the national competent authority of a Member State, which will make the application
and any supplementary information supplied by the applicant available to the European Food Safety
Authority (EFSA).
1.2. Interpretation of the Terms of Reference
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an
opinion on the scientific substantiation of a health claim related to: green kiwifruit and maintenance of
normal defecation.
The present opinion does not constitute, and cannot be construed as, an authorisation for the
marketing of green kiwifruit, a positive assessment of its safety, nor a decision on whether green
kiwifruit is, or is not, classified as a foodstuff. It should be noted that such an assessment is not
foreseen in the framework of Regulation (EC) No 1924/2006.
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions
of use as proposed by the applicant may be subject to changes, pending the outcome of the
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006.
2. Data and methodologies
2.1. Data
Information provided by the applicant
Food/constituent as stated by the applicant
According to the applicant, the food for which the health claim is made is ‘green kiwifruit (Actinidia
deliciosa (var. Hayward))’.
Health relationship as claimed by the applicant
According to the applicant, the health effect is related to ‘reduces gastrointestinal discomfort by the
normalization of bowel habit and a reduction in sensations associated with discomfort’. Following a
dialogue with EFSA and taking into account the proposed health relationship, the applicant agreed on
the claimed effect: ‘maintenance of normal defecation’.
Mechanism by which the food/constituent could exert the claimed effect as proposed by
the applicant
The applicant claims that the putative mechanisms by which kiwifruit exerts the claimed effect are
related to: altered intestinal motility (due to the presence of fibre and actinidin), changes in intestinal
permeability and mucus secretion (due to fibre, kissper (a kiwifruit peptide), phenolics and raphides),
altered faecal properties (due to fibre), and altered microbiota (due to fibre, phenolics and raphides).
Wording of the health claim as proposed by the applicant
The applicant originally proposed the following wording for the health claim: ‘Regular consumption
of green kiwifruit contributes to gastrointestinal comfort’ or ‘regular consumption of green kiwifruit
reduces gastrointestinal discomfort’. Following a dialogue with EFSA and taking into account the
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proposed health relationship, the applicant agreed on the following wording: ‘Regular consumption of
green kiwifruit maintains normal defecation’.
Specific conditions of use as proposed by the applicant
According to the applicant, the target population for the intended health claim is the general
population. The daily consumption of two green kiwifruits is recommended.
Data provided by the applicant
The health claim application on green kiwifruit and maintenance of normal defecation pursuant to
Article 13.5 of Regulation (EC) No 1924/2006, presented in a common and structured format as
outlined in the Scientific and technical guidance for the preparation and presentation of applications for
authorisation of health claims.
As outlined in the General guidance for stakeholders on health claim applications (EFSA NDA Panel,
2016a), it is the responsibility of the applicant to provide the totality of the available evidence.
2.2. Methodologies
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in
the EFSA general guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016a).
The scientific requirements for health claims related to the immune system, the gastrointestinal
tract and defence against pathogenic microorganisms are outlined in a specific EFSA guidance (EFSA
NDA Panel, 2016b).
The application does not contain data claimed as confidential and data claimed as proprietary.
3. Assessment
The approach used by the NDA Panel for the evaluation of health claims is explained in the General
scientific guidance for stakeholders on health claim applications (EFSA NDA Panel, 2016a). In assessing
each specific food/health relationship, which forms the basis of a health claim, the NDA
Panel considers the following key criteria:
i) the food/constituent is defined and characterised;
ii) the claimed effect is based on the essentiality of a nutrient; OR the claimed effect is defined
and is a beneficial physiological effect for the target population and can be measured in vivo
in humans;
iii) a cause and effect relationship is established between the consumption of the food/constituent
and the claimed effect (for the target group under the proposed conditions of use).
Each of these three criteria needs to be assessed by the NDA Panel with a favourable outcome for
a claim to be substantiated. In addition, an unfavourable outcome of the assessment of questions (i)
and/or (ii) precludes the scientific assessment of question (iii).
3.1. Characterisation of the food/constituent
The food/constituent proposed by the applicant as the subject of the health claim is ‘green kiwifruit
(Actinidia deliciosa var. Hayward)’.
Nutrient composition for green kiwifruit, as presented in the United States Department of
Agriculture (USDA database, 2019) National Nutrient Database for Standard Reference (released April
2018, revised April 2019) was provided. According to this database, 100 g of edible raw green kiwifruit
flesh contains 1.14 g protein, 14.7 g carbohydrates (including 9.0 g sugars), 0.52 g fat and 3.0 g
dietary fibre and provides 61 kcal (255 kJ) of energy. As a fresh fruit, the composition of kiwifruit
varies slightly as a function of maturity, growing region, local climatic factors and horticultural practices
(Taylor et al., 2003 unpublished). The kiwifruits supplied in the studies described in Section 3.3 had a
weight of between 120 and 150 g, corresponding to 90 and 115 g of raw flesh.
The variety Hayward is the main green kiwifruit variety currently available on the market. This was
also the variety that was used in all the human intervention studies described in Section 3.3.
Only the internal flesh of green kiwifruit is consumed, not the outer peel/skin.
Details related to the harvesting process and stability information were provided in the application.
The Panel considers that green kiwifruit (Actinidia deliciosa var. Hayward), which is the subject of
the health claim, is sufficiently characterised.
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3.2. Relevance of the claimed effect to human health
The claimed effect as agreed with the applicant is ‘maintenance of normal defecation’. The
proposed target population is the general population.
Maintenance of normal defecation may be assessed by a number of outcome variables which could
provide information about the function and eventually about the underlying mechanism of action,
some of which may be interrelated (e.g. stool frequency, stool consistency, sensation of complete/
incomplete evacuation, faecal bulk, transit time). It is considered a beneficial physiological effect
provided it does not result in diarrhoea (EFSA NDA Panel, 2016b).
The Panel considers that maintenance of normal defecation is a beneficial physiological effect
provided that it does not result in diarrhoea.
3.3. Scientific substantiation of the claimed effect
The applicant performed three literature searches (October 2013, January 2018 and July 2020) in
Web of Knowledge, Web of Science, Current Contents Connect, Medline, PubMed, Sci-Finder Scholar,
EBSCO, Science Direct, Google Scholar, ProQuest Science & Technology, Scopus, Scirus, Index New
Zealand, Discover, Worldcat.org, Patentscope, European Patent Scope, NZ Patent Office, USA Patent &
Trademark Office, International Clinical Trials Registry, and Zespri International Ltd – Internal Reports
with the following key words: “kiwi*”, “actin*”, “kiwifruit*”, “Actinidia”, “actinidin”, “Chinese gooseberry”,
“bowel”, “comfort”, laxati*”, “constipat*”, “regular*”, “gastro*”, “gut”, “stool”, “pain”, “frequency”,
“transit”, “health”, “quality of life”, “intestine*”, and “digest*”.
The applicant identified 18 human intervention studies (14 published and 4 unpublished) and one
systematic review of human intervention studies (Lister and Drummond, 2014, unpublished) as being
pertinent to the claim.
The study by Hill (2002) was submitted as a short report, the study by Hiele (2010), unpublished) as a
PowerPoint presentation, and the study by Weir (2010) was reported as US Patent application only. All
these references did not contain sufficient information for the scientific evaluation of the study. Six
studies were performed with foods other than fresh green kiwifruits. These included the study by Udani
and Bloom (2013), Ansell et al. (2015), Feng et al. (2015) and Kindleysides et al. (2015) performed with
powdered extract from kiwifruit, by Uebaba et al. (2009) carried out with fresh kiwifruit freeze-dried
juice, and by Weir et al. (2018) with freeze-dried green kiwifruit extract. Three studies (Chan et al.,
2007; Ohsawa et al., 2010; Cunillera et al., 2015) were single arm, uncontrolled studies and the article
by Chang et al. (2010) described a two-arm (kiwifruit vs control) non-randomised study with inconsistent
reporting of results between tables and figures. The Panel considers that no conclusions can be drawn
from these studies for the scientific substantiation of the claim.
The systematic review by Lister and Drummond (2014, unpublished) covered 12 human intervention
trials of which 11 trials were also submitted separately by the applicant. The only study that was not
present in the application received by EFSA (Marzo and Cunillera, 2013, unpublished) was a one-arm
uncontrolled study from which no conclusion can be drawn for the scientific evaluation of the claim.
Therefore, this review was not considered further in the scientific evaluation of the claim.
Six human intervention studies reported in five publications (Rush et al., 2002; Wilkinson-Smith
et al. 2019; Caballero et al., 2020; Drummond et al., 2020 unpublished study report; Chey et al.,
2021) were evaluated by the Panel for the scientific substantiation of the claim. All of them were
conducted with green kiwifruit var. Hayward. The Panel notes that all these human intervention studies
submitted had different limitations (e.g. short duration, studies not specifically designed to evaluate
outcomes related to normal defecation, small sample sizes, shortcomings in the statistical analyses, a
cross-over study in which a carry-over effect could not be excluded) and could not be used on their
own for the scientific substantiation of the claim.
The six pertinent human intervention studies are described below in terms of study population
(healthy or constipated) in the order of decreasing sample size.
Studies in healthy individuals
Rush et al. (2002) reported on two randomised cross-over studies with a similar study design on
stool frequency, stool bulk and stool consistency without specifying a primary outcome. In the first
study, 48 healthy individuals (30 females) with an age between 18 and 50 years were included. Study
periods in study 1 lasted six weeks. In the second study, 42 healthy volunteers (25 women) > 60 years
of age were recruited, of whom 38 completed the study, including seven that took laxatives regularly.
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Study periods in study 2 lasted 3 weeks. One green kiwifruit per 30 kg body weight per day (i.e. 2 or
3 kiwifruits daily depending on body weight) was used in one period of the studies. In the other
period, the participants consumed their habitual diet without kiwifruit. There was no wash-out period.
The participants were trained to keep a defecation diary. The diary was collected and checked with the
participants each week. Stool consistency had to be rated in the diary on a 4-point scale (runny, soft,
medium and hard). There was no information on the validation of this scale. Therefore, the results for
stool consistency have not been further considered. Even though the study was a cross-over study, it
was analysed as parallel study using the independent t-test to compare changes from baseline
between kiwifruit and no kiwifruit consumption. Results are presented in the paper by period for each
of the two sequences separately.
For study 1, data for each period were presented for the first and second 3 weeks of the period.
No single value for the entire period was reported. In the kiwifruit period, daily stool frequency for
participants in sequence 1 (kiwifruit second) was (mean  SEM) 1.29  0.03 (first three weeks) and
1.29  0.03 (second three weeks) and 1.33  0.03 and 1.40  0.04 in sequence 2 (kiwifruit first),
respectively. Without kiwifruit, daily stool frequency in sequence 1 was 1.26  0.03 and 1.18  0.04
and for those in sequence 2 1.30  0.04 and 1.26  0.04.
In study 2, kiwifruit consumption led to daily stool frequency of 1.43 ( 0.11) in sequence 1
(kiwifruit second) and in sequence 2 (kiwifruit first) 1.24 ( 0.11), while without kiwifruit stool
frequency was 1.17  0.07 and 1.24  0.09 for individuals in sequences 1 and 2, respectively.
The Panel notes that these cross-over studies, in which a primary outcome was not specified, were
analysed as parallel studies. Therefore, the results of the statistical analyses are not interpretable.
Wilkinson-Smith et al. (2019) performed a randomised, cross-over study that evaluated the effect
of consumption of green kiwifruits vs an energy-matched control drink containing maltodextrin on
colonic transit time (longitudinal relaxation time was the primary outcome of the study), stool
frequency, stool consistency and abdominal symptoms. Sixteen healthy adults (six females, range 21–
33 years) were recruited. Two kiwifruits twice daily (i.e. four fruits a day) or the control drink were
consumed for three days. Stool frequency was documented in a questionnaire and assessed on the
days of consumption of test products plus one day. Stool consistency was evaluated using the Bristol
stool scale and transit time by an MRI technique. Statistical comparisons were performed by the
Wilcoxon signed-rank test (kiwifruit compared to control) without correction for multiple testing.
Fourteen participants completed the study. Daily stool frequency was significantly higher during the
kiwifruit period compared with the control period (1.46  0.66 vs 1.14  0.46 stools per day; p =
0.034). Stools during the kiwifruit period were also softer (p = 0.011). Whole gut transit time was not
affected.
The Panel notes that this study with a small sample size and a short duration was not designed to
investigate changes in defecation and that the number of kiwifruits consumed in the study was twice
the amount proposed in the conditions of use.
Caballero et al. (2020) carried out a two-period cross-over, randomised, single-blind study to
evaluate the effect of consumption of a low-flatulogenic diet (excluding legumes, vegetables, garlic,
onion, cucumber, nuts, cereals, whole-meal bread, and fizzy drinks) plus green kiwifruit in comparison
to a low flatulogenic diet alone on intestinal gas production (primary outcome), stool frequency, stool
consistency and abdominal symptoms. Eleven healthy individuals (8 women; age range 18–23 years)
were recruited and all completed the study. Two two-week periods were compared: a period on the
low-flatulogenic diet (without kiwifruits) and a period in which two green kiwifruits per day where
consumed while being on the same low-flatulogenic diet. Stool frequency was assessed by using a
diary in which participants recorded the number of daily bowel movements and stool consistency by
the Bristol stool scale. Comparisons of normally distributed data were performed by the Student t-test
for paired data. Non-parametric data were compared using the Wilcoxon signed-rank test. Intake of
kiwifruits was associated with more frequent bowel movements per day (mean  SE: 1.8  0.1 vs 1.5
 0.1 off-kiwifruit; p = 0.001). The consumption of kiwifruits did not lead to diarrhoea. The results
were not corrected for multiple testing. There was no effect on stool consistency.
The Panel notes that this study with a small sample size and a short duration was not designed to
investigate changes in defecation.
The Panel notes that weekly differences in changes from baseline in stool frequency between
periods (as calculated by EFSA) ranged between around 0.5 and 2 stools per week in favour of green
kiwifruit in the four studies that investigated the outcome in healthy individuals. In the studies that
used the validated Bristol stool scale to assess stool consistency, the consumption of kiwifruit led to
softer stools in one study, in which, however, four kiwifruits per day were consumed. This was not the
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case in the study in which two kiwifruits per day were used, but which also had a considerably smaller
sample size (n = 8 as compared to n = 14).
Studies in individuals with constipation
The study by Drummond et al. (2020 unpublished study report) was a randomised, single-blind
(blinded to investigators and statisticians), two-period, cross-over study which compared the effect of
consumption of kiwifruit (two kiwifruits per day) with psyllium (7.5 g/day) consumed for four weeks on
stool frequency (Complete Spontaneous Bowel Movements (CSBM) was the primary outcome of the
study), stool consistency and gastrointestinal discomfort. Both interventions (kiwifruit and psyllium)
provided about 6 g/day of dietary fibre. The study was carried out in three research centres localised
in New Zealand, Japan and Italy. Three groups of subjects (in total 172 participants (136 females,
mean age  SD 35.5  14.6 years)) were recruited for the study: a) individuals with functional
constipation according to ROME III criteria (FC; n = 52), b) individuals with irritable bowel syndrome
and constipation of mild or moderate severity according to ROME III criteria (IBS-C; n = 58) and c)
healthy controls (HC, n = 62). The 16-week study period consisted of a 2-week run-in, two 4-week
intervention periods with a 4-week washout in between and a 2-week follow-up period. Randomisation
was stratified by the groups mentioned above in the centres in Japan and Italy, but not in New
Zealand, and balanced within blocks of 4, with 10 blocks per stratum. Bowel movements were
recorded daily by participants in a diary. Stool consistency was evaluated using the Bristol stool scale.
Gastrointestinal transit times were determined using a wireless motility capsule device (in Italy and
New Zealand) or radiopaque method (in Japan) in half of the participants. Statistical analyses were
performed on an intention-to-treat (ITT) basis separately for each study group (HC, FC and IBS-C) and
for the combined constipated group (FC + IBS-C), using a mixed model (Proc Mixed, SAS/STAT 14.1)
with fixed effects for gender, intervention sequence, and treatment, using subject as random effect.
For the present opinion, the results in the combined constipated group (FC + IBS-C) were considered.
Using the method described by Shen and Lu (2006), a significant carry-over effect in the IBS-C group
was observed showing that the increase in stool frequency was higher in the kiwifruit period that
followed the psyllium period than in the kiwifruit period that preceded the psyllium period. However,
no significant effect of sequence was observed in the mixed model. The treatment per time interaction
in the mixed model using absolute weekly stool frequencies was not statistically significant (week 4:
5.49 (95% CI 4.81–6.18) vs 4.45 (3.81–5.08) stools per week for kiwifruit vs psyllium). In an analysis
on weekly changes from baseline, using a repeated measures analysis of variance with centre,
sequence, period and treatment as fixed effects and subject as random effect, a statistically significant
increase in stool frequency was observed for kiwifruit as compared with psyllium (i.e. increase in 1.69
(95% CI 1.11–2.28 vs 0.90 (95% CI: 0.39–1.42) stools per week, p = 0.038). The consumption of
kiwifruits led to softer stools as compared with the consumption of psyllium (p = 0.011) but did not
cause diarrhoea. Gastrointestinal transit time was not different between periods.
The Panel notes that a possible carry-over effect from the psyllium into the kiwifruit period cannot
be excluded and that the results were not consistent between the statistical analysis based on absolute
values and the one based on changes from baseline.
In a parallel, three-arm study Chey et al. (2020) studied the effect of green kiwifruit (n = 30; two
kiwifruits per day), prunes (n = 26; 100 g/day) and psyllium (n = 23; 12 g/day) consumed for 4 weeks
on a number of outcomes related to bowel function in 79 adults (69 females, median age 42.7 years)
with functional constipation and with IBS-C according to ROME IV criteria. All three interventions
contained 6 g/day of fibre. While the prunes and psyllium arms of the study were randomised, the
kiwifruit arm was not. The primary endpoint was the proportion of patients in each group reporting an
increase of ≥ 1 CSBM per week compared to baseline for at least 2 of 4 treatment weeks. Bowel
movements were recorded daily by participants in a diary. Stool consistency was evaluated using the
Bristol stool scale. Differences in the primary endpoint were assessed using chi squared tests and one
sample test of binomial proportions were used to generate the upper and lower limits of the 95% CI.
Differences in stool frequency for weeks 3 and 4 averaged were compared using ANOVA. One
individual in the kiwifruit group, two in the prunes group and one in the psyllium group did not
complete the study. The CSBM responder rate was 45% for the kiwi group (13/29; 95% CI (0.27,
0.63)), 64% for the psyllium group (14/22; 95% CI (0.44, 0.84)) and 67% for the prunes group (16/
24; 95% CI (0.48, 0.86)), with no statistically significant differences between groups (p = 0.22). There
were no statistically significant differences between groups. Weekly CSBM increased significantly within
groups, on average by 1.0 with the consumption of kiwifruit, by 1.7 on psyllium and by 2.7 on prunes.
At week 4, average weekly stool frequency amounted to 2.3 on kiwifruit, 3.0 on psyllium and 4.1 on
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prunes (read from graph). No between group comparisons are reported for the difference in stool
frequency. There were no differences between groups with respect to stool consistency, even though a
statistically significant improvement in stool consistency from baseline was reported for the kiwifruit
and the prune groups, but not for the psyllium group.
The Panel notes that this study was not randomised with respect to the kiwifruit intervention.
The Panel notes that in none of the studies described above diarrhoea was reported to have
occurred in conjunction with kiwifruit consumption.
The Panel notes that in the two studies in constipated individuals in which the effect of green
kiwifruit was investigated in comparison to a positive control (i.e. psyllium or prunes), the effect of
consumption of green kiwifruit on stool frequency appeared to be at least similar to the effect of the
positive control. In one study, the consumption of green kiwifruit led to softer stools than the
consumption of psyllium, while in the other study no statistically significant differences were observed,
even though significant improvement in stool consistency from baseline was reported for the kiwifruit
and the prune groups, but not for the psyllium group.
The Panel considers that notwithstanding the methodological limitations of the studies, overall, the
evidence derived from six studies suggests a favourable effect of the consumption of two green
kiwifruits a day on an increase in stool frequency that ranges between around 0.5 to 2 extra stools per
week in healthy individuals. When compared to a positive control (psyllium or prunes) in individuals
with constipation, the effect on stool frequency appeared to be at least similar to the positive control.
Two out of four studies in which a validated instrument was used to assess stool consistency also
indicated an effect on stool consistency.
Mechanism of action
The Panel notes that kiwifruit contains approximately 3% dietary fibre (USDA, 2019) comprised of
one-third soluble fibre and two-thirds insoluble fibre. The soluble fibre fraction contains almost
exclusively pectic polysaccharides, whereas the insoluble fibre is mostly cellulose and hemicellulose.
Insoluble components of dietary fibre are not broken down by microorganisms in the colon and are
one determinant of faecal bulk, not only by their presence but also by retaining water within the
cellular structure. The soluble components are metabolised by the microbiota and by this stimulate
microbial growth which in turn impacts on faecal bulk (Cummings, 2001). It is established that an
increased faecal mass promotes normal laxation (Gelinas, 2013; Korczak et al., 2017; Bharucha and
Lacy, 2020) that is mediated by an increasing diameter of the lumen of the colon, thereby decreasing
intraluminal pressure and allowing increased forward flow of the faeces (Gregory and Strong, 2005).
The Panel notes that the flesh of two large green kiwifruits (i.e. around 200 g of flesh) will provide
around 6 g of dietary fibre.
The Panel considers that there is evidence for a plausible mechanism by which green kiwifruit
exerts an effect on normal defecation.
Weighing of the evidence
In weighing the evidence, the Panel took into account that the results of the six human intervention
studies from which conclusions could be drawn for the scientific substantiation of the claim, are
consistent with respect to an effect of consuming daily between two and four green kiwifruits var.
Hayward on an increase in stool frequency. The Panel also took into account that two out of four
studies in which a validated instrument was used to assess stool consistency showed an effect also on
stool consistency and that there is evidence for a plausible mechanism by which kiwifruit could exert
an effect on normal defecation. Finally, the Panel also took into account that the consumption of
kiwifruit in the studies did not result in diarrhoea.
The Panel concludes that a cause and effect relationship has been established between the
consumption of green kiwifruit (Actinidia deliciosa var. Hayward) and maintenance of normal
defecation. However, the scientific evidence does not establish that the effect of green kiwifruit on
normal defecation is over and above what could be expected by its content in dietary fibre.
4. Panel comments on the proposed wording
The Panel considers that the following wordings reflect the scientific evidence: ‘consumption of
kiwifruit contributes to the maintenance of normal defecation’.
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5. Conditions and possible restrictions of use
The Panel considers that in order to obtain the claimed effect, two large green kiwifruits (i.e.
around 200 g of kiwi flesh)/day should be consumed. The target population is the general population.
Conclusions
On the basis of the data presented, the Panel concludes that:
• The food/constituent, green kiwifruit (lat. Actinidia deliciosa var. Hayward), which is the subject
of the health claim, is sufficiently characterised.
• The claimed effect is ‘maintenance of normal defecation’. The target population proposed by
the applicant is ‘the general population’. Maintenance of normal defecation is a beneficial
physiological effect provided that it does not result in diarrhoea.
• A cause and effect relationship has been established between the consumption of green
kiwifruit (lat. Actinidia deliciosa var. Hayward) and maintenance of normal defecation.
• The following wording reflects the scientific evidence: ‘consumption of kiwifruit contributes to
the maintenance of normal defecation’.
• In order to obtain the claimed effect, two large green kiwifruits (i.e. around 200 g of kiwi
flesh)/day should be consumed. The target population is the general population.
Documentation as provided to EFSA
Health claim application on ‘green kiwifruit’ and ‘maintenance of normal defecation’ pursuant to
Article 13(5) of Regulation (EC) No 1924/2006 (Claim serial No: 0498_BE). Submitted by Zespri
International Limited, 400 Maunganui Road, Mt. Maunganui 3116, New Zealand.
Steps taken by EFSA
1) This application was received by EFSA on 19/08/2020.
2) The scope of the application was proposed to fall under a health claim based on newly
developed scientific evidence.
3) The scientific evaluation procedure started on 21/10/2020.
4) On 9/11/2020, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientific evaluation was suspended on 8/12/2020 and was restarted on 22/12/2020, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
5) On 26/01/2021, the Working Group on Claims of the NDA Panel agreed on a list of questions
for the applicant to provide additional information to accompany the application. The
scientific evaluation was suspended on 13/02/2021 and was restarted on 27/02/2021, in
compliance with Article 18(3) of Regulation (EC) No 1924/2006.
6) During its meeting on 7/05/2021, the NDA Panel, having evaluated the data, adopted an
opinion on the scientific substantiation of a health claim related to the consumption of green
kiwifruit (lat. Actinidia deliciosa var. Hayward) and maintenance of normal defecation.
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ANOVA analysis of variance
BSFS Bristol Stool Form Scale
CI confidential Interval
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CSBM Complete Spontaneous Bowel Movements
FC Functional Constipation
GSRS Gastrointestinal Symptom Rating Scale
HC healthy controls
IBS irritable Bowel Syndrome
IBS-C irritable Bowel Syndrome with constipation
ITT Intention to treat
MRI magnetic resonance imaging
NDA Panel Panel on Nutrition, Novel Foods and Food Allergens
PP Per protocol
QoL quality of Life
SCFA short-chain fatty acid
SE standard error
SEM standard error of mean
USDA United States Department of Agriculture
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